Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Every Other Week XmAb®2513 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients With Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma

NCT00606645 is registered in ClinicalTrials.gov with Xencor, Inc. as lead sponsor.

NCT NCT00606645
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00606645 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Every Other Week XmAb®2513 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients With Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Lead sponsor
Xencor, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2007
Completion date
April 30, 2010
Enrollment
23 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, hodgkin lymphoma